1. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report;Anderson;Case Rep Womens Health,2020
2. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial;Gautret;Int J Antimicrob Agents,2020
3. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro;Wang;Cell Res,2020
4. Compassionate use of remdesivir for patients with severe Covid-19;Grein;N Engl J Med,2020
5. 5. United States. U.S. Department of Health and Human Services (HHS). Food and Drug Administration (FDA). Center for Biologics Evaluation and Research (CBER). Investigational COVID-19 covalescent plasma: guidance for industry. Maryland: FDA; 2021 [cited 2020 June 29]. Available from: https://www.fda.gov/media/136798/download